Immune system activation via exposure to live attenuated Mycobacterium bovis antigens

This entry does not refer to a specific molecular target such as a receptor, enzyme, transporter, or defined protein complex. Instead, it describes an **immunological process**—the activation of the immune system following exposure to live attenuated *Mycobacterium bovis* antigens such as those found in the BCG vaccine. Upon exposure: • Antigen-presenting cells—including dendritic cells—process and present mycobacterial antigens. • Hydrophobic lipopeptides from *M. bovis* are presented via MHC class II molecules. • This stimulates robust proliferation and cytokine release from CD4+ T helper cells; CD8+ and γδTCR+ lymphocytes also participate. • The dominant immune profile is Th1-biased with high levels of IFN‐γ; other cytokines like IL‐22 and TNF‐α may also be elevated[1][2][3]. • These responses are essential for protection against tuberculosis but do not correspond to modulation at a single molecular target. Because this entry describes an immunological event rather than an individual molecule or canonical drug target structure—and lacks specificity regarding any one receptor/protein—it should not be classified as a therapeutic "target" per standard pharmacological definitions[1][2].

Other names

Immune response to Mycobacterium bovis antigensBCG-induced immune activationCellular response to M. bovis vaccination

The mechanism involves **exposure of the immune system**—primarily antigen-presenting cells and T lymphocytes—to live attenuated *Mycobacterium bovis* antigens. This leads to the presentation of mycobacterial lipopeptides and other hydrophobic antigens via MHC class II molecules on APCs, stimulating polyfunctional T cell responses dominated by Th1-type cytokines such as IFN‐γ. The process is critical for both innate and adaptive immunity against mycobacterial infection[1][2].